Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5182546 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| SCHEMBL5556969 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| SCHEMBL27416532 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| SCHEMBL27958482 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| SCHEMBL22807088 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| SCHEMBL27879770 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| SCHEMBL5708958 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NAAA | |
| Methane SCHEMBL11850443 | 0.96 | CA12 (0.53) | CA12CA1CA2CA9NAAA | |
| SCHEMBL29282005 | 0.96 | CA12 (0.53) | CA12CA1CA2CA9NAAA | |
| SCHEMBL447115 | 0.96 | CA12 (0.53) | CA12CA1CA2CA9NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | claimed |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-18 | — | — | US | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | claimed |
| CN-115677890-A | Dendritic fluorescent liquid crystal polymer with aggregation-induced emission characteristic and preparation method thereof | 湖南理工学院 | 2023-02-03 | — | — | CN | claimed |
| WO-2023009500-A1 | PENTAAZA MACROCYCLIC RING COMPLEX FOR ENHANCED SURGICAL TREATMENT | GALERA LABS, LLC (US) | 2023-02-02 | — | — | WO | claimed |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | GALERA LABS, LLC | 2022-07-21 | — | — | US | claimed |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | BIOSSIL INC. (CA) | 2022-04-21 | — | — | US | claimed |
| WO-1997006830-A1 | METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| WO-1997006824-A2 | BIOCONJUGATES OF MANGANESE COMPLEXES AND THEIR APPLICATION AS CATALYSTS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| EP-0758892-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1997-02-26 | — | — | EP | claimed |
| EP-0756495-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1997-02-05 | — | — | EP | claimed |
| WO-1996040658-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES | MONSANTO COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1995031197-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | claimed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | claimed |
| EP-0080409-B1 | FLEXIBLE ELASTOMER COMPOSITION OF EPICHLOROHYDRINE | Commissariat à l'Energie Atomique (FR) | 1986-02-26 | — | — | EP | claimed |
| US-4414343-A | Epichlorohydrin-based flexible elastomer composition | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1983-11-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | MC2R, GHRHR, GNRHR | CA12 308/4885CA1 834/4885CA2 3964/4885 |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | HDAC1, HDAC8, SIRT3 | CA12 49/4885CA1 192/4885CA2 817/4885 |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | SOD1, MSH6, SLC30A6 | CA12 131/4885CA1 159/4885CA2 163/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | CA12 497/4885CA1 1182/4885CA2 877/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | CA12 497/4885CA1 1182/4885CA2 877/4885 |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | CA12 453/4885CA1 1382/4885CA2 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.